Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.43 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.43 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082599 | 1.00 | SLC7A5 (0.54) | SLC7A5CYP2D6CYP2C19SLC1A2SLC1A3 | |
| SCHEMBL27734500 | 0.84 | CYP2D6 (0.45) | SLC7A5CYP2D6CYP2C19MAPTHPGD | |
| SCHEMBL14381150 | 0.84 | CYP2D6 (0.45) | SLC7A5CYP2D6CYP2C19MAPTHPGD | |
| SCHEMBL25407409 | 0.84 | SLC7A5 (0.48) | SLC7A5CYP2D6CYP2C19SLC1A2SLC1A3 | |
| SCHEMBL8231097 | 0.84 | SLC7A5 (0.48) | SLC7A5CYP2D6CYP2C19SLC1A2SLC1A3 | |
| SCHEMBL1768706 | 0.81 | SLC1A1 (0.50) | SLC7A5CYP2D6CYP2C19SLC1A2SLC1A3 | |
| SCHEMBL1768701 | 0.81 | SLC1A1 (0.50) | SLC7A5CYP2D6CYP2C19SLC1A2SLC1A3 | |
| SCHEMBL1768507 | 0.80 | GFPT1 (0.46) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| SCHEMBL28095721 | 0.80 | GFPT1 (0.46) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| SCHEMBL402417 | 0.79 | GRIK1 (0.47) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101400699-A | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | CN | claimed |
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
| EP-3169403-B9 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| WO-2023288313-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-9624268-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2017011820-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2016-05-26 | — | — | US | disclosed |
| WO-2016011208-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| EP-2948450-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | SLC7A5 2674/4885CYP2D6 2043/4885CYP2C19 2118/4885 |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | SLC7A5 2234/4885CYP2D6 543/4885CYP2C19 691/4885 |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | SLC7A5 3470/4885CYP2D6 4660/4885CYP2C19 2419/4885 |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | SLC7A5 3283/4885CYP2D6 4259/4885CYP2C19 1244/4885 |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | SLC7A5 1279/4885CYP2D6 4658/4885CYP2C19 4621/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | SLC7A5 3470/4885CYP2D6 4660/4885CYP2C19 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.